NCT03164447View on ClinicalTrials.gov

UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients

PHASE2UnknownINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

March 31, 2024

Study Completion Date

May 31, 2024

Conditions

HIV-1 Infection

Interventions

BIOLOGICAL

UB-421

Monoclonal antibody by IV infusion

DRUG

Optimized background therapy (OBT)

The prescribed OBT must contain at least one agent to which the participant's virus is known to be fully sensitive.

Sponsors

Lead Sponsor

United BioPharma

All Listed Sponsors

lead

United BioPharma

INDUSTRY

NCT03164447 - UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients | Biotech Hunter | Biotech Hunter